[
  {
    "ts": null,
    "headline": "Jim Cramer on Eli Lilly Stock: “It Just Got Pole-Axed, Laid to Waste”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer highlighted the reasons behind the stock’s decline recently. He remarked: “Last and least, I look at the drug stocks and I can’t believe how awful they really are, with now Eli Lilly last joining the ugly fray with its less […]",
    "url": "https://finnhub.io/api/news?id=697e30f6d9f64b542f00d0ccad648a69564c6f0cffae57b3025844890f67f740",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755113844,
      "headline": "Jim Cramer on Eli Lilly Stock: “It Just Got Pole-Axed, Laid to Waste”",
      "id": 136339405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer highlighted the reasons behind the stock’s decline recently. He remarked: “Last and least, I look at the drug stocks and I can’t believe how awful they really are, with now Eli Lilly last joining the ugly fray with its less […]",
      "url": "https://finnhub.io/api/news?id=697e30f6d9f64b542f00d0ccad648a69564c6f0cffae57b3025844890f67f740"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Popped Today",
    "summary": "The GLP-1 weight loss wars have gone global.",
    "url": "https://finnhub.io/api/news?id=a80d4c440efe8dab946cf8c5273083398a734339baf6e2402881f560585366a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755112801,
      "headline": "Why Eli Lilly Stock Popped Today",
      "id": 136339406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The GLP-1 weight loss wars have gone global.",
      "url": "https://finnhub.io/api/news?id=a80d4c440efe8dab946cf8c5273083398a734339baf6e2402881f560585366a4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Trades Up, Here Is Why",
    "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of significant insider buying by top executives, including the CEO, sent the stock rebounding from a recent selloff.",
    "url": "https://finnhub.io/api/news?id=4dbb3d9754047a7336ad5131d8bf7a0fcb55b4f57ea487e7cea38ec7533a44d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755111667,
      "headline": "Eli Lilly (LLY) Stock Trades Up, Here Is Why",
      "id": 136339407,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of significant insider buying by top executives, including the CEO, sent the stock rebounding from a recent selloff.",
      "url": "https://finnhub.io/api/news?id=4dbb3d9754047a7336ad5131d8bf7a0fcb55b4f57ea487e7cea38ec7533a44d1"
    }
  },
  {
    "ts": null,
    "headline": "Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst",
    "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and expand treatment options beyond injections. The study, which began in January 2025, will assess the safety, tolerability, pharmacokinetics and weight-loss efficacy of once-daily oral dosing over a",
    "url": "https://finnhub.io/api/news?id=bb356bc0f2e26b577849709486af2f1e51e794395e0017077eaee12c46315070",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755109835,
      "headline": "Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst",
      "id": 136339408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and expand treatment options beyond injections. The study, which began in January 2025, will assess the safety, tolerability, pharmacokinetics and weight-loss efficacy of once-daily oral dosing over a",
      "url": "https://finnhub.io/api/news?id=bb356bc0f2e26b577849709486af2f1e51e794395e0017077eaee12c46315070"
    }
  },
  {
    "ts": null,
    "headline": "3 Unusual Insider Transactions you Should Know About",
    "summary": "While no single indicator can guarantee a stock's performance, the pattern of insider transactions can provide a powerful glimpse into a company's prospects.",
    "url": "https://finnhub.io/api/news?id=24f96c3beab2dcc2a3d7592bdb7dad5478de5732d041085aea20979b44bf3794",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755108960,
      "headline": "3 Unusual Insider Transactions you Should Know About",
      "id": 136339409,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While no single indicator can guarantee a stock's performance, the pattern of insider transactions can provide a powerful glimpse into a company's prospects.",
      "url": "https://finnhub.io/api/news?id=24f96c3beab2dcc2a3d7592bdb7dad5478de5732d041085aea20979b44bf3794"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Fires Up GLP-1 Race in India With Mounjaro Pen Launch",
    "summary": "Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market",
    "url": "https://finnhub.io/api/news?id=5627cde1e0b79b2ef470adbcd77dbf53e2e2f365044b6635d3c1e16fe70fa947",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755107336,
      "headline": "Eli Lilly Fires Up GLP-1 Race in India With Mounjaro Pen Launch",
      "id": 136339410,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's Kwikpen debut intensifies rivalry with Novo Nordisk's Wegovy in the world's most populous diabetes market",
      "url": "https://finnhub.io/api/news?id=5627cde1e0b79b2ef470adbcd77dbf53e2e2f365044b6635d3c1e16fe70fa947"
    }
  },
  {
    "ts": null,
    "headline": "Scholar Rock Holding: Upcoming Milestone Approaches",
    "summary": "With a market cap of $3.1 billion, Scholar Rock Holding Corporation appears fairly valued for now. Click here to read an analysis of SRRK stock now.",
    "url": "https://finnhub.io/api/news?id=322994fed4b380affd85d4b7193b9748e1030b15403e7ae7be9e65c46df69764",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755106198,
      "headline": "Scholar Rock Holding: Upcoming Milestone Approaches",
      "id": 136341141,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473708731/image_1473708731.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "With a market cap of $3.1 billion, Scholar Rock Holding Corporation appears fairly valued for now. Click here to read an analysis of SRRK stock now.",
      "url": "https://finnhub.io/api/news?id=322994fed4b380affd85d4b7193b9748e1030b15403e7ae7be9e65c46df69764"
    }
  },
  {
    "ts": null,
    "headline": "Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?",
    "summary": "Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts",
    "url": "https://finnhub.io/api/news?id=6ae8ed4f7793c02a01e9869027bef19731999ab40c7f641e9014273649cf89e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755101820,
      "headline": "Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?",
      "id": 136339411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts",
      "url": "https://finnhub.io/api/news?id=6ae8ed4f7793c02a01e9869027bef19731999ab40c7f641e9014273649cf89e0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs",
    "summary": "Eli Lilly said it will vigorously defend the allegations brought by the state of Texas.",
    "url": "https://finnhub.io/api/news?id=549f5e9bc335412991913d9b2503f04c9a1503457d947903528c00a564f5e945",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755099010,
      "headline": "Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs",
      "id": 136339412,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly said it will vigorously defend the allegations brought by the state of Texas.",
      "url": "https://finnhub.io/api/news?id=549f5e9bc335412991913d9b2503f04c9a1503457d947903528c00a564f5e945"
    }
  },
  {
    "ts": null,
    "headline": "LLY: Eli Lilly Stock Tanks -- Insiders Rush In With Millions",
    "summary": "Lilly's Worst Selloff Triggers Insider Stock Grab",
    "url": "https://finnhub.io/api/news?id=1f400a6587098d0487cc0ea12a1c3757bf2bf6bb88a1359e7c0911492a2909fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755096912,
      "headline": "LLY: Eli Lilly Stock Tanks -- Insiders Rush In With Millions",
      "id": 136339413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's Worst Selloff Triggers Insider Stock Grab",
      "url": "https://finnhub.io/api/news?id=1f400a6587098d0487cc0ea12a1c3757bf2bf6bb88a1359e7c0911492a2909fc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Rises 6% So Far in August: How to Play the Stock",
    "summary": "NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.",
    "url": "https://finnhub.io/api/news?id=79e22f5a8e8427f057aa778f10c5357294f8b3ecf717c0b86f700d34f3840017",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755096420,
      "headline": "Novo Nordisk Rises 6% So Far in August: How to Play the Stock",
      "id": 136339414,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.",
      "url": "https://finnhub.io/api/news?id=79e22f5a8e8427f057aa778f10c5357294f8b3ecf717c0b86f700d34f3840017"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB",
    "summary": "The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enh",
    "url": "https://finnhub.io/api/news?id=016bf5ea612edf87ebda38b794a7bda822ac8a84d056d2e01aedd09cb5f7de92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755091980,
      "headline": "Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB",
      "id": 136328328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enh",
      "url": "https://finnhub.io/api/news?id=016bf5ea612edf87ebda38b794a7bda822ac8a84d056d2e01aedd09cb5f7de92"
    }
  },
  {
    "ts": null,
    "headline": "Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound",
    "summary": "Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss. Paxton alleges the company’s conduct violated state fraud prevention laws and defrauded taxpayers through improper Medicaid claims. According to the complaint, Eli Lilly provided illegal incentives to healthcare",
    "url": "https://finnhub.io/api/news?id=caf338afe3bb968d2dc03087bf043fae6614036c23e2b0046b311c38b1c85aa9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755087359,
      "headline": "Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound",
      "id": 136328196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss. Paxton alleges the company’s conduct violated state fraud prevention laws and defrauded taxpayers through improper Medicaid claims. According to the complaint, Eli Lilly provided illegal incentives to healthcare",
      "url": "https://finnhub.io/api/news?id=caf338afe3bb968d2dc03087bf043fae6614036c23e2b0046b311c38b1c85aa9"
    }
  },
  {
    "ts": null,
    "headline": "The 3 Things That Matter for Viking Therapeutics Now",
    "summary": "Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.",
    "url": "https://finnhub.io/api/news?id=3e4a25034aa53c73869d41c4816bdf561caba8423becf5a982f12eec5848b931",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755072600,
      "headline": "The 3 Things That Matter for Viking Therapeutics Now",
      "id": 136328197,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.",
      "url": "https://finnhub.io/api/news?id=3e4a25034aa53c73869d41c4816bdf561caba8423becf5a982f12eec5848b931"
    }
  },
  {
    "ts": null,
    "headline": "Lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry",
    "summary": "Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk. Lilly said in June it received approval from India's drug regulator for its once-weekly Mounjaro Kwikpen, two days after Novo Nordisk launched Wegovy in multiple dose strengths in a similar pen device. Mounjaro Kwikpen is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with pricing calculated for a month's supply.",
    "url": "https://finnhub.io/api/news?id=5b8bf3c743c59f7774a6458e2c444485f67043f7a81b5c1556dc394d80c150a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755070814,
      "headline": "Lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry",
      "id": 136328198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk. Lilly said in June it received approval from India's drug regulator for its once-weekly Mounjaro Kwikpen, two days after Novo Nordisk launched Wegovy in multiple dose strengths in a similar pen device. Mounjaro Kwikpen is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with pricing calculated for a month's supply.",
      "url": "https://finnhub.io/api/news?id=5b8bf3c743c59f7774a6458e2c444485f67043f7a81b5c1556dc394d80c150a4"
    }
  }
]